- Presentations during the École Thématique de Criblage conference in Marseille and the European College of neuropsychopharmacology conference in Spain
- Nomination of Mathieu Charvériat, Theranexus Chief Scientific Officer , to the scientific committee of the French Society of Pharmacology and Therapeutics (SFPT)
Lyon, 1 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that Mathieu Charvériat, Chief Scientific Officer and co-founder of Theranexus, has been nominated to the Scientific Committee of the French Society of Pharmacology and Therapeutics, (SFPT). The company is also announcing the presentation of two scientific posters during the École Thématique de Criblage (ETC) and the European College of Neuropsychopharmacology (ECNP) conferences taking place in early October.
With his deep experience of the field of neuropharmacology and notably his work on the modulation of medicines targeting neurons and glial cells, Mathieu Charvériat, Chief Scientific Officer of Theranexus, was appointed to the SFPT Scientific Committee. The mission of the SFPT is to support therapeutic innovations and contribute to the best use of medicines and medical devices for patients.
Furthermore, during the 9th École Thématique de Criblage (ETC) conference from 2nd to 4th October in Marseille, Theranexus will present recent data obtained through a new phenotypic screening tool that aims at identifying novel glial connexin modulators. This work is the product of a collaboration between Theranexus and the French Atomic Energy Commission (CEA) Biosciences and Biotechnologies Institute of Grenoble.
Finally, during the European College of Neuropsychopharmacology (ECNP) conference, the largest conference on applied and translational neurosciences which will take place in Barcelona from 6th to 9th October, Theranexus will present the preclinical data for its drug candidate THN201. This drug candidate targets neurocognitive disorders associated with Alzheimer's disease, and recently entered its first clinical trial assessing the safety and efficacy of THN201. The preclinical data, that will be presented, shows, using various preclinical models, that THN201 has a superior effect compared to the standard of care drug for this symptom.
“These acknowledgements reaffirm the strong scientific and technological base of Theranexus that contributes to the development and value-creation of its therapeutic strategy and its portfolio of clinical drug candidates”, concludes Franck Mouthon, CEO of Theranexus.
|ABOUT THERANEXUS |
Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus.com
Financial and Administrative Director
ACTUS finance & communication
Caroline Lesage / Théo Martin
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
+ 33 (0)6 07 76 82 83